Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) will be announcing its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Autolus Therapeutics Trading Up 1.2 %
Shares of AUTL stock traded up $0.04 during trading hours on Tuesday, reaching $3.38. 854,638 shares of the stock traded hands, compared to its average volume of 1,380,637. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $899.38 million, a PE ratio of -2.91 and a beta of 2.04. Autolus Therapeutics has a 1-year low of $3.06 and a 1-year high of $7.45. The business has a fifty day moving average price of $4.00 and a 200 day moving average price of $4.03.
Autolus Therapeutics Company Profile
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
